$1.27
-0.04 (-3.05%)
Open$1.31
Previous Close$1.31
Day High$1.33
Day Low$1.26
52W High$5.55
52W Low$0.83
Volume—
Avg Volume358.5K
Market Cap87.34M
P/E Ratio—
EPS$-1.57
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+3,466.1% upside
Current
$1.27
$1.27
Target
$45.29
$45.29
$33.37
$45.29 avg
$67.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 16.99M | 59.72M | 61.79M |
| Net Income | -81,375,709 | -17,457,928 | -16,293,891 |
| Profit Margin | -479.0% | -29.2% | -26.4% |
| EBITDA | -82,212,161 | -19,228,267 | -21,164,861 |
| Free Cash Flow | — | -18,637,383 | -17,592,445 |
| Rev Growth | — | -4.4% | +5.4% |
| Debt/Equity | 0.00 | 0.30 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |